Narasin
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Narasin
- DrugBank Accession Number
- DB11432
- Background
Narasin is an agent with coccidiostatic and antibacterial properties.
- Type
- Small Molecule
- Groups
- Experimental, Vet approved
- Structure
- Weight
- Average: 765.038
Monoisotopic: 764.507463138 - Chemical Formula
- C43H72O11
- Synonyms
- Narasin
- Narasin A
- Narasine
- Narasino
- Narasinum
- External IDs
- C 7819B
- C-7819B
- COMPD-79891
- Lilly 79891
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The risk or severity of bleeding can be increased when Narasin is combined with Acenocoumarol. Ambroxol The risk or severity of methemoglobinemia can be increased when Narasin is combined with Ambroxol. Articaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Articaine. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Narasin. Benzocaine The risk or severity of methemoglobinemia can be increased when Narasin is combined with Benzocaine. - Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Monteban (veterinary)
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diterpene glycosides. These are diterpenoids in which an isoprene unit is glycosylated.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Terpene glycosides
- Direct Parent
- Diterpene glycosides
- Alternative Parents
- Diterpenoids / Fatty alcohols / Branched fatty acids / Heterocyclic fatty acids / Hydroxy fatty acids / Ketals / Beta-hydroxy ketones / Oxanes / Pyrans / Tertiary alcohols show 8 more
- Substituents
- Acetal / Alcohol / Aliphatic heteropolycyclic compound / Beta-hydroxy ketone / Branched fatty acid / Carbonyl group / Carboxylic acid / Carboxylic acid derivative / Dialkyl ether / Diterpene glycoside show 20 more
- Molecular Framework
- Aliphatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- DZY9VU539P
- CAS number
- 55134-13-9
- InChI Key
- VHKXXVVRRDYCIK-CWCPJSEDSA-N
- InChI
- InChI=1S/C43H72O11/c1-12-30(35(46)27(8)34(45)28(9)36-23(4)21-24(5)37(51-36)31(13-2)39(47)48)38-25(6)22-26(7)42(52-38)18-15-32(44)43(54-42)20-19-40(11,53-43)33-16-17-41(49,14-3)29(10)50-33/h15,18,23-34,36-38,44-45,49H,12-14,16-17,19-22H2,1-11H3,(H,47,48)/t23-,24-,25-,26+,27-,28-,29-,30-,31+,32+,33+,34+,36+,37+,38-,40-,41+,42-,43-/m0/s1
- IUPAC Name
- (2R)-2-[(2R,3S,5S,6R)-6-[(2S,3S,4S,6R)-6-[(2S,5S,7R,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.5^{7}.3^{5}]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-3,5-dimethyloxan-2-yl]butanoic acid
- SMILES
- [H][C@@]1(CC[C@](O)(CC)[C@H](C)O1)[C@]1(C)CC[C@]2(O1)O[C@@]1(O[C@]([H])([C@@H](CC)C(=O)[C@@H](C)[C@@H](O)[C@H](C)[C@]3([H])O[C@@]([H])([C@@H](CC)C(O)=O)[C@@H](C)C[C@@H]3C)[C@@H](C)C[C@H]1C)C=C[C@H]2O
References
- General References
- Behr KP, Luders H, Glunder G, Friederichs M: [Narasin poisoning in turkeys]. Dtsch Tierarztl Wochenschr. 1988 Mar;95(3):107-8, 110-1. [Article]
- Salyi G, Szabo E, Bago G, Banhidi G, Szilagyi M: Narasin poisoning in turkeys. Acta Vet Hung. 1988;36(1-2):107-15. [Article]
- Litjens JB: [A case of narasin poisoning in turkeys]. Tijdschr Diergeneeskd. 1985 Sep 1;110(17):665. [Article]
- Van Halderen A, Bastianello SS, Fourie N, Zumpt IF: An outbreak of narasin poisoning in swine. J S Afr Vet Assoc. 1993 Mar;64(1):43-6. [Article]
- Salles MS, Lombardo de Barros CS, Barros SS: Ionophore antibiotic (narasin) poisoning in rabbits. Vet Hum Toxicol. 1994 Oct;36(5):437-44. [Article]
- Jeffers TK, Tonkinson LV, Camp LJ, Murphy CN, Schlegel BF, Snyder DL, Young DC: Field experience trials comparing narasin and monensin. Poult Sci. 1988 Jul;67(7):1058-61. [Article]
- Jeffers TK, Tonkinson LV, Callender ME: Anticoccidial efficacy of narasin in battery cage trials. Poult Sci. 1988 Jul;67(7):1043-9. [Article]
- Hussey RL, Macy TD, Moran J, Loh A: Liquid chromatographic determination of narasin in feed premixes. J Assoc Off Anal Chem. 1985 May-Jun;68(3):417-8. [Article]
- Occolowitz JL, Berg DH, Debono M, Hamill RL: The structure of narasin and a related ionophore. Biomed Mass Spectrom. 1976 Dec;3(6):272-7. [Article]
- Jeffers TK, Tonkinson LV, Callender ME, Schlegel BF, Reid WM: Anticoccidial efficacy of narasin in floor pen trials. Poult Sci. 1988 Jul;67(7):1050-7. [Article]
- External Links
- KEGG Drug
- D05122
- ChemSpider
- 58911
- 1314370
- ChEMBL
- CHEMBL2104423
- ZINC
- ZINC000085540282
- Wikipedia
- Narasin
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Granule Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00241 mg/mL ALOGPS logP 4.7 ALOGPS logP 7.88 Chemaxon logS -5.5 ALOGPS pKa (Strongest Acidic) 4.5 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 11 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 161.21 Å2 Chemaxon Rotatable Bond Count 12 Chemaxon Refractivity 204.54 m3·mol-1 Chemaxon Polarizability 85.69 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 315.9728249 predictedDarkChem Lite v0.1.0 [M-H]- 252.44041 predictedDeepCCS 1.0 (2019) [M+H]+ 315.4761249 predictedDarkChem Lite v0.1.0 [M+H]+ 254.16411 predictedDeepCCS 1.0 (2019) [M+Na]+ 314.4203249 predictedDarkChem Lite v0.1.0 [M+Na]+ 260.49307 predictedDeepCCS 1.0 (2019)
Drug created at February 25, 2016 18:44 / Updated at February 21, 2021 18:53